Correlation between depression and quality of life in patients with Parkinson's disease

Su, Wen; Liu, Huijing; Jiang, Yanyan; Li, Shuhua; Jin, Ying; Yan, Chuanzhu; Chen, Haibo

doi:10.1016/j.clineuro.2021.106523

Cited by 28 publications

(24 citation statements)

References 25 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Depression is the most common non-motor disorder and affects 40–50% of patients with PD ( 3 ). Depression in patients with PD is closely related to poor quality of life ( 4 ), such as altered mood, cardiovascular sympathetic dysfunction, sleep disturbance, and even active suicidal ideation ( 5 – 7 ). Early diagnosis of depression in patients with PD can help improve their quality of life; however, the pathophysiological mechanism of depression in PD is poorly understood.…”

Section: Introductionmentioning

confidence: 99%

Identifying Depression in Parkinson's Disease by Using Combined Diffusion Tensor Imaging and Support Vector Machine

Yang

Pan

et al. 2022

Front. Neurol.

View full text Add to dashboard Cite

ObjectiveTo investigate white matter microstructural alterations in Parkinson's disease (PD) patients with depression using the whole-brain diffusion tensor imaging (DTI) method and to explore the DTI–based machine learning model in identifying depressed PD (dPD).MethodsThe DTI data were collected from 37 patients with dPD and 35 patients with non-depressed PD (ndPD), and 25 healthy control (HC) subjects were collected as the reference. An atlas-based analysis method was used to compare fractional anisotropy (FA) and mean diffusivity (MD) among the three groups. A support vector machine (SVM) was trained to examine the probability of discriminating between dPD and ndPD.ResultsAs compared with ndPD, dPD group exhibited significantly decreased FA in the bilateral corticospinal tract, right cingulum (cingulate gyrus), left cingulum hippocampus, bilateral inferior longitudinal fasciculus, and bilateral superior longitudinal fasciculus, and increased MD in the right cingulum (cingulate gyrus) and left superior longitudinal fasciculus-temporal part. For discriminating between dPD and ndPD, the SVM model with DTI features exhibited an accuracy of 0.70 in the training set [area under the receiver operating characteristic curve (ROC) was 0.78] and an accuracy of 0.73 in the test set (area under the ROC was 0.71).ConclusionDepression in PD is associated with white matter microstructural alterations. The SVM machine learning model based on DTI parameters could be valuable for the individualized diagnosis of dPD.

show abstract

Section: Introductionmentioning

confidence: 99%

Identifying Depression in Parkinson's Disease by Using Combined Diffusion Tensor Imaging and Support Vector Machine

Yang

Pan

et al. 2022

Front. Neurol.

View full text Add to dashboard Cite

show abstract

“…According to several studies, it was observed that affective disorders, particularly depression [ 28 ], may have a direct negative influence on the QoL of PD patients [ 29 , 30 ]. In this research [ 31 ], a scale for nonmotor PD symptoms (NMS) was used, and relative impact of each clinical subscale on QoL was assessed.…”

Section: Discussionmentioning

confidence: 99%

Gastrointestinal Dysfunction Impact on Life Quality in a Cohort of Russian Patients with Parkinson’s Disease I-III H&Y Stage

Пилипович

Воробьева

Makarov

et al. 2022

Parkinson's Disease

View full text Add to dashboard Cite

Background. There are still no clearly proven methods to slow down or stop the progression of Parkinson’s disease (PD). Thus, improving the quality of life (QoL) of patients with PD becomes of primary importance. Autonomic dysfunction and its symptoms are known to worsen the quality of life in PD, but the degree of this influence is underinvestigated. Particularly, impacts of the separate significant gastrointestinal symptoms, such as dyspepsia, constipation, and abdominal pain, in PD should be more precisely evaluated with the help of specific scales. Objective. To assess the impacts of gastrointestinal dysfunction and its symptoms on PD patient’s QoL using PDQ-39. Methods. 111 PD patients in the I-III Hoehn and Yahr (H&Y) stage were enrolled in the study. The following scales were applied: UPDRS III, PDQ-39, GSRS, GDSS, MMSE, BDI, STAI-S, and STAI-T. Results. The linear regression model showed that the PDQ-39 SI depended on summary assessments GSRS-SI (β = 0.333, p < 0.001 ), BDI (β = 0.463, p < 0.001 ), and UPDRS III (β = 0.163, p < 0.05 ). The use of the stepwise method, adding GSRS-SI and UPDRS III scores to the BDI predictor, improved the model (R2 increased from 0.454 to 0.574). The investigation of GSRS domain’s influence revealed that PDQ-39 SI had a significant correlation with almost all of them, but the regression analysis showed significant QoL impacts of only two factors: constipation and abdominal pain (β = 0.288, p < 0.01 and β = 0.243, p < 0.05 accordingly). Conclusions. Our results suggest a considerable negative influence of depression and gastrointestinal dysfunction (especially constipation and abdominal pain) on QoL of patients with PD. Their impact on QoL in patients with I-III H&Y stages of PD is more significant than that of motor symptoms. Therefore, the correction of depression and gastrointestinal dysfunction should be prioritized in PD therapy.

show abstract

“…Depression is a frequent comorbidity in PD that has a notable negative effect on health-related and global QoL of patients with PD, not only major and minor depression, but also subD [ 1 , 22 ]. Importantly, we observed that mood improvement 6 months after starting with safinamide correlated with health-related QoL improvement.…”

Section: Discussionmentioning

confidence: 99%

“…Systematic reviews of depression in epidemiologic PD studies describe a combined prevalence about 35% [ 23 ], although some publications report frequencies over 50% [ 13 , 24 ]. This prevalence may be higher in patients with disease later stages [ 22 , 25 – 27 ] or women [ 12 , 26 ], although depression‐type frequency or BDI-II score does not seem to change with disease duration [ 13 ]. Furthermore, patients with disease later stages that present motor fluctuations suffer more frequent dysthymia and anxiety symptoms, unrelated to levodopa wearing off or controlled treatment response of fluctuations [ 28 ].…”

Section: Discussionmentioning

confidence: 99%

Effectiveness of Safinamide over Mood in Parkinson’s Disease Patients: Secondary Analysis of the Open-label Study SAFINONMOTOR

et al. 2021

View full text Add to dashboard Cite

Introduction Mood disorders are frequent in Parkinson’s disease (PD) and a favorable effect of safinamide on mood has been observed. We aimed to analyze the effectiveness of safinamide on mood as a secondary objective from the SAFINONMOTOR (an open-label study of the effectiveness of SAFInamide on NON-MOTOR symptoms in patients with Parkinson’s disease) study. Methods SAFINONMOTOR is a prospective open-label single-arm study conducted in five centers from Spain. Patients with PD were required to have at baseline a Non-Motor Symptoms Scale (NMSS) total score of at least 40. In this analysis, the changes from V1 (baseline) to V4 (6 months ± 1 month) in the BDI-II (Beck Depression Inventory-II), NMSS mood/apathy domain, and PDQ-39 (Parkinson’s Disease Questionnaire-39) emotional well‐being domain were analyzed. Depression was identified and classified (DSM-IV and Judd criteria) at baseline and at the end of follow-up as major depression (MD), minor depression (mD), subthreshold depression (subD), and non-depression (nonD). Results Fifty patients with PD were included (age 68.5 ± 9.12 years; 58% women; 6.4 ± 5.1 years from diagnosis) and 44 patients (88%) completed the follow-up at 6 months. The BDI-II total score was reduced by 35.9% (from 15.88 ± 10.46 at V1 to 10.18 ± 6.76 at V4; p < 0.0001). A significant decrease in the NMSS mood/apathy domain and PDQ-39 emotional well‐being domain was observed as well ( p < 0.0001). At baseline, 52% of the patients presented MD, 34% mD, 12% subD, and 2% nonD whereas at V4 the percentages were 31.8%, 34.1%, 22.7%, and 11.4%, respectively ( p = 0.029). Conclusions Safinamide improves mood in patients with PD at 6 months. Supplementary Information The online version contains supplementary material available at 10.1007/s12325-021-01873-w.

show abstract

Correlation between depression and quality of life in patients with Parkinson's disease

Cited by 28 publications

References 25 publications

Identifying Depression in Parkinson's Disease by Using Combined Diffusion Tensor Imaging and Support Vector Machine

Identifying Depression in Parkinson's Disease by Using Combined Diffusion Tensor Imaging and Support Vector Machine

Gastrointestinal Dysfunction Impact on Life Quality in a Cohort of Russian Patients with Parkinson’s Disease I-III H&Y Stage

Effectiveness of Safinamide over Mood in Parkinson’s Disease Patients: Secondary Analysis of the Open-label Study SAFINONMOTOR

Contact Info

Product

Resources

About